Register for our free email digests:
Latest From Polyphor Ltd.
The Swiss major is paying up to $387m to get access to potential natural antibiotics that have not been analyzed previously, 'owing to historical technology limitations.'
An IMI-backed consortium is developing inhaled formulations of the privately held Swiss company's murepavadin and Novartis's tobramycin to reduce infections suffered by bronchiectasis and cystic fibrosis patients.
Regulatory incentives have been successful at attracting developers to antibiotic R&D, but significant medical advances have stubbornly remained rare. Now the pipeline has produced the first novel antibiotic to receive breakthrough status from US FDA and some Phase III trials are raising the efficacy bar to superiority.
Development is most advanced in C. difficile infection, but US FDA's exploration of pathways to expedite single pathogen treatments could spur earlier-stage QIDP projects targeting Staphylococcus and Pseudomonas species.
- Drug Discovery Tools
- Therapeutic Areas
- Immune Disorders
- Infectious & Viral Diseases
- Respiratory, Pulmonary
- Western Europe
- Parent & Subsidiaries
- Polyphor Ltd.
- Senior Management
Giacomo Di Nepi, CEO
Kalina Scott, CFO
Daniel Obrecht, PhD, CSO
Helmut Kessmann, PhD, Head, Bus. Dev.
Debra Barker, MD, CMO & Chief Dev. Officer
- Contact Info
Phone: (41) 61 567 16 00
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.